Literature DB >> 35000210

Serum periostin among infants with severe bronchiolitis and risk of developing asthma: A prospective multicenter cohort study.

Makiko Nanishi1, Michimasa Fujiogi1, Robert J Freishtat2,3, Claire E Hoptay4, Cindy S Bauer5, Michelle D Stevenson6, Carlos A Camargo1, Kohei Hasegawa1.   

Abstract

BACKGROUND: Infants hospitalized for bronchiolitis (severe bronchiolitis) are at high risk for developing childhood asthma. However, the pathobiological link between these conditions remains unclear. We examined the longitudinal relationship of periostin (an extracellular matrix protein upregulated in response to type 2 inflammation) during bronchiolitis with the subsequent development of asthma.
METHODS: In a 17-center prospective cohort study of infants (aged <1 year) with severe bronchiolitis, we measured the serum periostin level at hospitalization and grouped infants into 3 groups: low, intermediate, and high levels. We examined their association with asthma development by age 6 years and investigated effect modification by allergic predisposition (eg, infant's IgE sensitization).
RESULTS: The analytic cohort consists of 847 infants with severe bronchiolitis (median age, 3 months). Overall, 28% developed asthma by age 6 years. In the multivariable model adjusting for nine patient-level factors, compared to the low periostin group, the asthma risk was significantly higher among infants in the intermediate group (23% vs. 32%, OR 1.68, 95%CI 1.12-2.51, p = .01) and non-significantly higher in the high-level group (28%, OR 1.29, 95%CI 0.86-1.95, p = .22). In the stratified analysis, infants with IgE sensitization had a significantly higher risk for developing asthma (intermediate group, OR 4.76, 95%CI 1.70-13.3, p = .002; high group, OR 3.19, 95%CI 1.08-9.36, p = .04). By contrast, infants without IgE sensitization did not have a significantly higher risk (p > .15).
CONCLUSIONS: In infants with severe bronchiolitis, serum periostin level at bronchiolitis hospitalization was associated with asthma risk by age 6 years, particularly among infants with an allergic predisposition.
© 2022 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  allergic predisposition; asthma; bronchiolitis; children; periostin

Mesh:

Substances:

Year:  2022        PMID: 35000210      PMCID: PMC9247040          DOI: 10.1111/all.15216

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   14.710


  37 in total

Review 1.  Periostin: An emerging biomarker for allergic diseases.

Authors:  Kenji Izuhara; Satoshi Nunomura; Yasuhiro Nanri; Junya Ono; Masayuki Takai; Atsushi Kawaguchi
Journal:  Allergy       Date:  2019-05-03       Impact factor: 13.146

2.  Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.

Authors:  Philip E Silkoff; Michel Laviolette; Dave Singh; J Mark FitzGerald; Steven Kelsen; Vibeke Backer; Celeste M Porsbjerg; Pierre-Olivier Girodet; Patrick Berger; Joel N Kline; Geoffrey Chupp; Vedrana S Susulic; Elliot S Barnathan; Frédéric Baribaud; Matthew J Loza
Journal:  J Allergy Clin Immunol       Date:  2017-01-13       Impact factor: 10.793

3.  Age-related changes in serum periostin level in allergic and non-allergic children.

Authors:  Hiroko Fujitani; Saki Kasuga; Takuma Ishihara; Yusuke Higa; Shiori Fujikawa; Nobuo Ohta; Junya Ono; Kenji Izuhara; Haruo Shintaku
Journal:  Allergol Int       Date:  2019-01-31       Impact factor: 5.836

4.  [Effects decomposition in mediation analysis: a numerical example].

Authors:  Daniela Zugna; Lorenzo Richiardi
Journal:  Epidemiol Prev       Date:  2018 Mar-Apr       Impact factor: 1.901

5.  Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease.

Authors:  R Caswell-Smith; A Hosking; T Cripps; C Holweg; J Matthews; M Holliday; C Maillot; J Fingleton; M Weatherall; I Braithwaite; R Beasley
Journal:  Clin Exp Allergy       Date:  2016-06-28       Impact factor: 5.018

6.  Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for bronchiolitis.

Authors:  Kohei Hasegawa; Jonathan M Mansbach; Nadim J Ajami; Janice A Espinola; David M Henke; Joseph F Petrosino; Pedro A Piedra; Chad A Shaw; Ashley F Sullivan; Carlos A Camargo
Journal:  Eur Respir J       Date:  2016-10-06       Impact factor: 16.671

7.  Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis.

Authors:  Kohei Hasegawa; Jonathan M Mansbach; Nadim J Ajami; Joseph F Petrosino; Robert J Freishtat; Stephen J Teach; Pedro A Piedra; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2016-11-12       Impact factor: 10.793

8.  Serum periostin relates to type-2 inflammation and lung function in asthma: Data from the large population-based cohort Swedish GA(2)LEN.

Authors:  A James; C Janson; A Malinovschi; C Holweg; K Alving; J Ono; S Ohta; A Ek; R Middelveld; B Dahlén; B Forsberg; K Izuhara; S-E Dahlén
Journal:  Allergy       Date:  2017-05-22       Impact factor: 13.146

9.  Periostin as a biomarker for the diagnosis of pediatric asthma.

Authors:  Takashi Inoue; Kenichi Akashi; Masako Watanabe; Yuichi Ikeda; Shuichi Ashizuka; Takanori Motoki; Ryohei Suzuki; Nagatoshi Sagara; Noriyuki Yanagida; Sakura Sato; Motohiro Ebisawa; Shoichiro Ohta; Jyunya Ono; Kenji Izuhara; Toshio Katsunuma
Journal:  Pediatr Allergy Immunol       Date:  2016-05-18       Impact factor: 6.377

10.  Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma.

Authors:  Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Brennan Harmon; Jonathan M Mansbach; Pedro A Piedra; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa
Journal:  Nat Commun       Date:  2021-06-14       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.